Philip E Silkoff1, Michel Laviolette2, Dave Singh3, J Mark FitzGerald4, Steven Kelsen5, Vibeke Backer6, Celeste M Porsbjerg6, Pierre-Olivier Girodet7, Patrick Berger7, Joel N Kline8, Geoffrey Chupp9, Vedrana S Susulic10, Elliot S Barnathan10, Frédéric Baribaud10, Matthew J Loza10. 1. Janssen Research & Development LLC, Spring House, Pa. Electronic address: philsilkoff@gmail.com. 2. Institut Universitaire de Cardiologie et Pneumologie de Québec (IUCPQ), Quebec City, Quebec, Canada. 3. Centre for Respiratory Medicine and Allergy, University of Manchester, and the Medicines Evaluation Unit, University Hospital of South Manchester NHS Foundation Trust, Manchester, United Kingdom. 4. Institute for Heart and Lung Health, Lung Centre, Gordon and Leslie Diamond Health Care Centre, Vancouver, British Columbia, Canada. 5. Department of Thoracic Medicine and Surgery, Temple University School of Medicine, Philadelphia, Pa. 6. Respiratory Research Unit, Department of Respiratory Medicine, Bispebjerg University Hospital, Copenhagen, Denmark. 7. Université Bordeaux, Centre de Recherche Cardio-Thoracique de Bordeaux, Bordeaux, France. 8. Division of Pulmonary, Critical Care, and Occupational Medicine, University of Iowa, Iowa City, Iowa. 9. Yale School of Medicine, New Haven, Conn. 10. Janssen Research & Development LLC, Spring House, Pa.
Abstract
BACKGROUND: The Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study profiled patients with mild, moderate, and severe asthma and nonatopic healthy control subjects. OBJECTIVE: We explored this data set to define type 2 inflammation based on airway mucosal IL-13-driven gene expression and how this related to clinically accessible biomarkers. METHODS: IL-13-driven gene expression was evaluated in several human cell lines. We then defined type 2 status in 25 healthy subjects, 28 patients with mild asthma, 29 patients with moderate asthma, and 26 patients with severe asthma based on airway mucosal expression of (1) CCL26 (the most differentially expressed gene), (2) periostin, or (3) a multigene IL-13 in vitro signature (IVS). Clinically accessible biomarkers included fraction of exhaled nitric oxide (Feno) values, blood eosinophil (bEOS) counts, serum CCL26 expression, and serum CCL17 expression. RESULTS: Expression of airway mucosal CCL26, periostin, and IL-13-IVS all facilitated segregation of subjects into type 2-high and type 2-low asthmatic groups, but in the ADEPT study population CCL26 expression was optimal. All subjects with high airway mucosal CCL26 expression and moderate-to-severe asthma had Feno values (≥35 ppb) and/or high bEOS counts (≥300 cells/mm3) compared with a minority (36%) of subjects with low airway mucosal CCL26 expression. A combination of Feno values, bEOS counts, and serum CCL17 and CCL26 expression had 100% positive predictive value and 87% negative predictive value for airway mucosal CCL26-high status. Clinical variables did not differ between subjects with type 2-high and type 2-low status. Eosinophilic inflammation was associated with but not limited to airway mucosal type 2 gene expression. CONCLUSION: A panel of clinical biomarkers accurately classified type 2 status based on airway mucosal CCL26, periostin, or IL-13-IVS gene expression. Use of Feno values, bEOS counts, and serum marker levels (eg, CCL26 and CCL17) in combination might allow patient selection for novel type 2 therapeutics.
BACKGROUND: The Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study profiled patients with mild, moderate, and severe asthma and nonatopic healthy control subjects. OBJECTIVE: We explored this data set to define type 2 inflammation based on airway mucosal IL-13-driven gene expression and how this related to clinically accessible biomarkers. METHODS:IL-13-driven gene expression was evaluated in several human cell lines. We then defined type 2 status in 25 healthy subjects, 28 patients with mild asthma, 29 patients with moderate asthma, and 26 patients with severe asthma based on airway mucosal expression of (1) CCL26 (the most differentially expressed gene), (2) periostin, or (3) a multigene IL-13 in vitro signature (IVS). Clinically accessible biomarkers included fraction of exhaled nitric oxide (Feno) values, blood eosinophil (bEOS) counts, serum CCL26 expression, and serum CCL17 expression. RESULTS: Expression of airway mucosal CCL26, periostin, and IL-13-IVS all facilitated segregation of subjects into type 2-high and type 2-low asthmatic groups, but in the ADEPT study population CCL26 expression was optimal. All subjects with high airway mucosal CCL26 expression and moderate-to-severe asthma had Feno values (≥35 ppb) and/or high bEOS counts (≥300 cells/mm3) compared with a minority (36%) of subjects with low airway mucosal CCL26 expression. A combination of Feno values, bEOS counts, and serum CCL17 and CCL26 expression had 100% positive predictive value and 87% negative predictive value for airway mucosal CCL26-high status. Clinical variables did not differ between subjects with type 2-high and type 2-low status. Eosinophilic inflammation was associated with but not limited to airway mucosal type 2 gene expression. CONCLUSION: A panel of clinical biomarkers accurately classified type 2 status based on airway mucosal CCL26, periostin, or IL-13-IVS gene expression. Use of Feno values, bEOS counts, and serum marker levels (eg, CCL26 and CCL17) in combination might allow patient selection for novel type 2 therapeutics.
Authors: Whitney W Stevens; Anju T Peters; Bruce K Tan; Aiko I Klingler; Julie A Poposki; Kathryn E Hulse; Leslie C Grammer; Kevin C Welch; Stephanie S Smith; David B Conley; Robert C Kern; Robert P Schleimer; Atsushi Kato Journal: J Allergy Clin Immunol Pract Date: 2019-05-22
Authors: Makiko Nanishi; Michimasa Fujiogi; Robert J Freishtat; Claire E Hoptay; Cindy S Bauer; Michelle D Stevenson; Carlos A Camargo; Kohei Hasegawa Journal: Allergy Date: 2022-01-17 Impact factor: 14.710
Authors: Matthew J Loza; Ratko Djukanovic; Kian Fan Chung; Daniel Horowitz; Keying Ma; Patrick Branigan; Elliot S Barnathan; Vedrana S Susulic; Philip E Silkoff; Peter J Sterk; Frédéric Baribaud Journal: Respir Res Date: 2016-12-15
Authors: Man Jia; Xiaoyi Yan; Xinyu Jiang; Yunhui Wu; Jiayan Xu; Yaqi Meng; Yi Yang; Xia Shan; Xiuwedi Zhang; Shan Mao; Wei Gu; Stelios Pavlidis; Peter J Barnes; Ian M Adcock; Mao Huang; Xin Yao Journal: Am J Respir Crit Care Med Date: 2019-02-15 Impact factor: 30.528